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This study aims to describe the range of treatment
comparisons, study designs and quality of reporting of
randomized clinical trials (RCTs) in psoriasis published
in a variety of medical and dermatological journals,
and to analyze time trends with quality items. Hand-
searching of clinical trials of psoriasis published from
1977 to 2000 in 13 medical or dermatological journals,
selected as relevant to a European readership, was per-
formed. A total of 249 trials published in 226 papers
were classi¢ed as RCTs. Of these, 139 (55.8%) employed
a parallel control group design, 107 (43.0%) studies
adopted a self-control design and 3 (1.2%) a cross-over
design. The median number of patients recruited per
study was 40 (range 6^699). Overall, 55 di¡erent treat-
ment modalities, including topical, ultraviolet-based,
systemic, and other miscellaneous therapies were as-
sessed. Only 31 (12.5%) RCTs were comparative studies
of treatment modalities in di¡erent therapeutic classes.
Most of the studies were short-term with a median
study duration of 7 weeks (range 1^104), with only 18
studies (7.2%) lasting for more than four months. A
variety of outcome measures including 44 di¡erent
score systems were employed. According to the conclu-
sions of the authors, 196 (78.7%) studies were judged to
provide striking or de¢nite observations in favor of one
of the treatments examined. No important variations
over time were documented for quality items. Based
on our survey we have identi¢ed an enormous range of
treatments that have been evaluated for psoriasis over
the examined period. Most studies were short-term,
and only a handful compared treatment options in dif-
ferent therapeutic classes. Since we did not examine all
the relevant journals, the number of treatment options
may be even greater than we have documented.There is
an urgent need to reset the research agenda focusing on
long-term comparative RCTs. Editors of major medical
and dermatological journals are urged to take a role
in improving the quality of RCT reporting. J Invest
Dermatol 120:738 ^741, 2003
P
soriasis is a chronic skin disorder a¡ecting 1^3% of the
general population. It is characterized by multiple
erythematous and scaly plaques that may be dis¢gur-
ing and a course that is typically punctuated by exacer-
bations and remissions (Stern, 1997). The causes are
unknown but genetic^environmental interaction seems to o¡er
a plausible etiological explanation. Keratinocyte hyperprolifera-
tion and in£ammatory changes are constant pathological features
(Barker, 1991). Although the disease does not a¡ect mortality, it
may substantially a¡ect the quality of life and in several countries
it is a leading cause of hospitalization from a cutaneous disorder
(Perrott et al, 2000; Krueger et al, 2001). Despite the availability of
many di¡erent treatments, the management of psoriasis is consid-
ered to be far from satisfactory with marked variations among
countries and physicians (Stern et al, 1999; Van de Kerkhof et al,
2000; Zachariae et al, 2001). The EDEN psoriasis project is an on-
going survey of the quality (i.e., internal validity) and generaliz-
ability (i.e., external validity) of the therapeutic studies for
psoriasis published in a number of dermatological and medical
journals since 1977. This paper aims to describe the range of treat-
ment comparisons, study designs and quality of reporting of ran-
domized clinical trials (RCTs) published up to the end of 2000,
and to analyze time trends with quality items.
METHODS
Searching strategy for therapeutic studies This study was based on a
survey of published reports of original therapeutic studies of psoriasis, i.e.,
studies evaluating the intended e¡ect of a treatment for psoriasis. Our focus
was on quality assessment of original papers reported in full. Abstracts,
letters to the Editor, Congress proceedings, review papers, individual case
reports, clinical studies involving less than 5 patients, papers mainly
focusing on side-e¡ects of treatment, and studies that dealt only with the
articular symptoms of psoriatic arthritis were excluded.
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Papers were classi¢ed and assessed, employing a prede¢ned checklist
(available upon request from the corresponding author), by a pair of
investigators independently.
Selection of journals The following journals were selected on the basis
of a consensus among assessors taking into account journal impact factor,
continuous publication during the time interval examined, language
(restricted to English, French, German, and Italian), and relevance to an
European readership: Acta Dermato-Venereologica, Annales de Dermatologie
et de Venereologie, Archives of Dermatology, British Journal of Dermatology, British
Medical Journal, Clinical Experimental Dermatology, Dermatology, Giornale
Italiano di Dermatologia e Venereologia, Journal of the American Academy of
Dermatology, Journal of Investigative Dermatology, Journal of the American Medical
Association, Lancet, New England Journal of Medicine. Apart from two (Annales
de Dermatologie etVeŁ neŁ rologie and Giornale Italiano di Dermatologia eVenerologia),
all journals were published in the English language. Dermatology (formerly
Dermatologica) changed its publication policy from multilingual (German,
French and English) to English only, during the study period. Four
journals were general medical journals (British Medical Journal, Journal of the
American Medical Association, Lancet, New England Journal of Medicine).
Information on the impact factor was derived from data provided by the
Journal Citation Reports (JCR), annual publication from the Institute for
Scienti¢c Information/Thompson Scienti¢c for the year 1990 (referring to
the two previous years 1988^9).
Data abstraction The complete volumes of all journals of the years 1977^
2000 (including supplements) were hand-searched by a pair of investigators
independently. Each investigator searched between two and four journals.
Initially, based on our checklist, papers were classi¢ed either as therapeutic
studies lacking internal control, including studies without any explicit control
group and studies with external historical controls, or as studies with internal
control, including parallel concurrent control studies, self-controlled studies
(e.g., right/left body comparison studies) and crossover studies (Lavori et al,
1983; Bailar et al, 1984; Louis et al, 1984). For all these studies, the year
of publication, intervention(s) examined, country of the study, and total
number of patients included were reported. Subsequent evaluation was
limited to internally controlled studies. The following items were assessed
without making any judgment of the appropriateness of the methods applied
in any single paper: randomization, entry criteria, rejection log, distribution of
pretreatment variables, description of the blinding procedure(s), duration of
experimental treatment(s), dropout(s), e⁄cacy parameters, major end point(s),
statistical power calculation, appropriateness of the analysis according to time,
intention-to-treat analysis, con¢dence intervals, subgroup analyses, main
message of the study, appropriateness of the inference(s) (Chalmers et al, 1981;
DerSimonian et al, 1982). Whether the study reported any sponsorship by a
pharmaceutical company was also evaluated. Data were entered inde-
pendently by two investigators into a computer-based questionnaire.
Statistics These original datasets were assessed for agreement between
investigators. Subsequently, disagreements were resolved through discussions
between the two data abstractors or a third reviewer if needed. The
interrater agreement, assessed by calculating Cohen’s Kappa statistics,
ranged from 0.31 (sponsorship) to 0.76 (patient blinding) with most of the
other values exceeding 0.60. For the purpose of this study’s quality analysis,
only RCTs were considered, i.e., studies explicitly mentioning random-
ization as a means of allocating treatment. Descriptive statistics were
calculated for all the parameters assessed.
RESULTS
Number of studies per paper A total of 422 papers dealing
with the treatment of psoriasis were initially identi¢ed. Of all
the papers, 354 (83.9%) reported one study, while 68 (16.1%)
reported several studies with 49 (11.6%) papers reporting two
studies, 13 (3.0%) three and 6 (1.4%) four or more, giving a total
of 515 studies to be assessed. Of these, 249 (48.3%) studies
published in 226 papers were classi¢ed as RCTs. In particular,
194 papers reported one RCT as the only study, 14 papers
reported a combination of one RCT and one observational
study (usually a follow-up study of patients initially recruited in
the RCT), 14 papers reported two di¡erent RCTs, 3 papers
reported 3 di¡erent RCTs and one paper reported 4 di¡erent
RCTs. Details of the examined studies are reported in a
Table published with the web version of this paper (http://
www.blackwellpublishing.com/products/journals/suppmat/JID/
jid12145/jid12145sm.htm). The proportion of papers presenting at
least one RCT increased from 78 out of 202 (38.6%) during the
period 1977^88 to 148 out of 220 (67.3%) during the period 1989^
2000. Four journals (British Journal of Dermatology, Journal of the
American Academy of Dermatology, Dermatology, and Archives of
Dermatology) accounted for 314 (74.4%) of all papers. The same
journals accounted for 187 (82.7%) of the papers reporting a
RCT. Only 8 papers were published in the four general medical
journals. A total of 63 papers reporting a RCT came from the
United States, 58 from the United Kingdom, 18 from Germany, 17
from Denmark, 16 from the Netherlands, 11 from Sweden, 9 from
Finland, 6 from France, and 28 from other countries or
represented international collaboration.
Types of study design and patient numbers Of the 249 RCTs
identi¢ed, 139 (55.8%) had a parallel control group, 107 (43.0%)
studies adopted a self-control (e.g., right/left body comparison
in the same patient) design and 3 (1.2%) a cross-over design.
The median number of patients per RCT was 40 (range 6^699)
and only 85 (34.1%) of all the RCTs included more than 50
patients. Papers reporting on more than one study did not
include more patients than papers reporting on one single RCT.
The median number of patients enrolled per RCT was 40 in
papers reporting one study, 29 in papers reporting two studies
and 28 in papers reporting three or more studies. The median
number of patients was 32 (upper limit 354) for studies
published up to 1988 and 42 (upper limit 699) for studies
published from 1989 to 2000.
Description of participants A total of 138 RCTs (55.4%) made
statements about the patient recruitment process reporting
information on entry criteria and exclusions while 111 (44.6%)
RCTs either failed to mention any entry criteria or provided
poor information. As for the clinical variety of the patients
actually recruited, 196 (78.7%) RCTs dealt with psoriasis
vulgaris, either alone (134 studies) or in association with other
varieties (62 studies), a total of 17 studies concentrated on palmo-
plantar and other verieties of pustular psoriasis, 15 studies on nail/
scalp psoriasis, 2 studies on guttate psoriasis, and 19 studies on
unspeci¢ed varieties or forms of psoriasis. The disease was
usually described by topography and type of lesions while
disease duration was considered in 21 (8.4%) RCTs and previous
treatments in 67 (26.9%) RCTs.
Heterogeneity of treatments A total of 55 di¡erent treatment
modalities were evaluated in the RCTs with 28 (50.9%)
modalities being assessed in no more than one single RCT. This
summary statistic concerning treatment modalities does not
include dose variations of the same drug, drug combinations or
di¡erent modalities of application of the same topical agent. The
regimens tested could be classi¢ed into topical agents, ultraviolet
(UV) radiation regimens, including oral psoralens associated with
UVA radiation (PUVA) and UVB radiation, systemic treatments,
and other miscellaneous treatment modalities.Within each group
several treatment classes could be identi¢ed, e.g., the topicals
group included a range of treatments such as tar, vitamin D
derivatives, keratolytics, and topical steroids. Miscellaneous therapies
included plasmapheresis, psychotherapy, dietetic measures, radio-
therapy, and acupuncture. The large majority of the studies
compared the experimental treatment against placebo, or against
a drug within the same therapeutic class, e.g., studies of di¡erent
steroids. There were only 31 (12.4%) comparative studies of treat-
ments classi¢able into two or more di¡erent therapeutic classes.
These included 17 out of 120 (14.1%) RCTs assessing a topical
agent, 7 out of 46 (15.2%) RCTs assessing UV light treatment, 6
out of 75 (8.0%) RCTs assessing a systemic treatment, and one of
8 RCTs assessing treatment modalities not otherwise classi¢able.
We found only two RCTs contrasting two or more di¡erent
systemic treatments. They compared cyclosporine with etretinate
in 86 and 210 people, respectively (Italian Multicenter Study
Group on Cyclosporin in Psoriasis, 1993; Mahrle et al, 1995). No
single RCT included systemic methotrexate, a popular drug in
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many countries for severe psoriasis, in one of the study arms. Six
RCTs compared UV radiation therapies with a systemic
treatment, namely etretinate or acitretin. The median number
of patients enrolled per study was 40 (upper limit 699) for
RCTs involving topical therapies, 44 (upper limit 224) for RCTs
involving UV light therapies, 42 (upper limit 400) for
RCTs involving systemic therapies, and 25 (upper limit 145) for
RCTs involving miscellaneous therapies.
Study duration and outcome measures Most of the studies
were short-term, with a median study duration of 7 weeks
(range 1^104) and with only 18 studies (7.2%) lasting for more
than four months. A total of 39 studies (15.6%) gave no inform-
ation on the study duration. The median study duration was 6
weeks (upper limit 104) for RCTs involving topical therapies, 8
weeks (upper limit 30) for studies involving UV light treatment,
10 weeks (upper limit 52) for systemic therapies, and 6 weeks
(upper limit 28) for miscellaneous treatment modalities. The
median study duration was 7 weeks (upper limit 52 weeks) for
the studies published in the period 1977^88 and 8 weeks (upper
limits 104) for those published in the period 1989^2000.
A total of 171 (68.7%) studies summarized treatment responses
using a score system. Forty-four di¡erent score systems were employed
which, in variable ways, took into account clinical features such
as extent of skin lesions, degree of erythema and scaling. The
most popular scoring system was the so-called Psoriasis Area
and Severity Index (PASI) adopted by a total of 83 (33.3%)
studies. PASI is a scoring system only partly validated (Kirby
et al, 2001), made up of arbitrary numerical scores given to the
extension of skin lesions, erythema, scaling and in¢ltration. A
total of 99 (39.7%) studies assessed outcome as the attainment of
a clinical category, e.g., clearance. Only 9 (3.6%) studies consid-
ered maintenance of remission over time and relapse rates. A total
of 19 (7.6%) studies assessed patient’s preference or satisfaction and
only one paper evaluated quality of life. No paper assessed such factors
as the impact of treatment on accessory care and hospitalization.
Issues of blinding and dropouts A total of 166/249 (66.6%)
studies were declared as double blind, but of these only 48 gave
a satisfactory description of blinding procedures. Because of the
treatment modality or peculiar side-e¡ects, PUVA, UVB and
retinoids are particularly di⁄cult to blind. A satisfactory des-
cription of blinding procedures with these treatments was given
by 4/11, 5/10, and 4/17 double-blinded RCTs, respectively. A
satisfactory modality to blind outcome assessment was to have
di¡erent ¢nal assessors from the treating physicians. A total of
164 studies (65.9%) reported withdrawals. The median percentage
of drop-outs per study was 7%, with an upper range of 55%: 68
studies had up to 10% drop-outs, 61 studies 11% to 20% and 35
studies more than 20% drop-outs. Drop-outs were ignored in the
analysis of 152/164 (92.7%) studies. An intention to treat analysis
was reported in four out of 68 studies with up to 10% drop-outs,
7/61 studies with 11^20% drop-outs and in 4/35 studies with more
than 20% drop-outs.
Authors’ interpretation of data and sponsorship issues
According to the conclusion of the authors, 196 (78.7%) studies
were judged to provide striking or de¢nite observations in favor
of one of the treatments examined while 48 (19.3%) reported
negative results; in ¢ve studies unclear statements about treat-
ment results were provided.
In 138/226 (61.0%) papers reporting a RCT, sponsoring by a
pharmaceutical company was mentioned or made obvious by
the a⁄liation of the authors. Fifty-eight (25.7%) papers were
categorized as nonsponsored, while in 30 papers (13.3%)
sponsorship remained unclear. A total of 108 (78.2%) out of 138
sponsored papers and 41/58 (70.7%) nonsponsored papers pre-
sented at least one study reporting results in favor of one of the
treatments examined. The median number of patients enrolled
was 40 for sponsored and 38 for nonsponsored studies. The
median study duration was 7 weeks for sponsored and 8 weeks
for nonsponsored studies. No major di¡erence was observed
between sponsored and nonsponsored studies for quality items
such as entry criteria, blinding and analysis of drop-outs. The
proportion of sponsored papers was 57.7% (45 out of 78) up to
1988 and 62.8% (93 out of 148) from 1989 to 2000.
DISCUSSION
General poor quality and clinical usefulness of psoriasis
studies Based on our survey, published studies on the therapy
of psoriasis have been characterized, in the period analyzed and
limited to the examined journals, by an enormous range of
treatments that have been mainly evaluated in small, short-term
RCTs with a very limited number of comparative studies and a
heterogeneity of outcome measures. Frequent methodological
£aws were also documented, including the lack of presentation
of entry criteria, inadequate information on blinding proce-
dures, and failure to consider drop-outs in the analysis. A large
proportion of RCTs reported positive results. Our analyses
con¢rm and expand the results of previous surveys concerning
the quality of RCTs on psoriasis and other in£ammatory skin
diseases (Bigby et al, 1985; Marks et al, 1989; Petersen and
Kristensen, 1992;Williams and Seed, 1993; Ashcroft et al, 1999).
Potential limitations of this study There are aspects of our
survey that may limit the generalizability of the results.We dealt
only with reports published in full and restricted the survey to 13
journals. The journals were chosen based on a consensus which
took into account, among the others, impact factor, likely yield
of RCTs based on the work of the Cochrane Skin Group
specialized trials register, and relevance to a European readership.
Even if our study missed a small subset of published psoriasis
trials, it is not expected that important RCTs were overlooked
(Moher et al, 2000). Moreover, no substantial variations over time
were observed to suggest a modifying trend. Most of our main
results concerned objective aspects of RCTs such as type of
treatment arms, study size and duration. Since we did not
examine all the relevant journals, the number of treatment
options may be even greater than we have documented. Our
analysis is not a systematic review trying to summarize treatment
e⁄cacy but rather a broad overview of methods used in psoriasis
trials with emphasis on study design and quality of reporting. As
such it di¡ers from previous studies summarizing the evidence for
a given variety of psoriasis, e.g., severe psoriasis, or a single drug,
e.g., calcipotriol (Ashcroft et al, 2000; Gri⁄ths et al, 2000).
How is the agenda of psoriasis trials driven? It appears that
the development of new treatments for psoriasis follows a rather
repetitive pattern where important questions for clinicians and
their patients like the comparative value of di¡erent treatment
options and the long-term impact of the treatment on the
disease are scarcely considered. A large proportion of RCTs
(59%) are sponsored by pharmaceutical companies. New drugs
are being developed that include those that target memory-
e¡ector Tcells, e.g., alefacept (Ellis and Krueger, 2001), and cytokine
blocking agents, e.g., etanercept (Mease et al, 2000).
What is needed to address the problem Based on our survey
a number of suggestions can be made for future research.
1 Placebo use. There is a need to establish criteria for the use of
placebo and comparative treatments in this area. They should
be developed with the active and informed participation of
the public and should be considered by review boards and reg-
ulatory agencies. In principle, placebo use should be restricted
to the early phase of development of a new treatment. Subse-
quently, comparative studies are needed. The comparator treat-
ment should re£ect the usual clinical practice. Factorial design
can be considered for treatment combinations.
2 Study duration. Long-term results are simply not predictable
from short-term studies. Long-term ‘‘pragmatic’’ RCTs con-
ducted under conditions close to clinical practice are needed.
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Consensus should be reached on study duration to document
the e¡ects of suppressive and remitting therapies. Several treat-
ment cycles can be assessed as a way of maintaining remission.
3 Outcome measures. An array of clinical activity scores have
been developed, the most popular one being the PASI. There
is no documented evidence that such indices are a reliable sur-
rogate for outcomes that matter to the patient, like disease sup-
pression and duration of remission, patient satisfaction and
autonomy and disease-related quality of life. In the long term,
the duration of remission, the way the disease is controlled and
the treatment side-e¡ects are vitally important, and simple out-
come measures applicable in all patients seem to be preferable
(Wright, 2000). These may include the number of patients in
remission, the number of hospital admissions or ambulatory
consultations, or major disease £are-ups. Clearly, remission or
recurrence are not as frequent as less dramatic variations in dis-
ease activity measured by highly sensitive expanded complex
clinical scales (Al-Suwaidan and Feldman, 2000). This in turn
a¡ects the sample size calculation.
4 Handling of drop-outs. Drop-outs merit special attention
since they may strongly re£ect dissatisfaction with treatment
(Schi¡ner et al, 2001). They cannot be simply ignored. Both in-
tention-to-treat and per-protocol analyses should be presented.
5 Systematic reviews. The large number of RCTs in this area
may point to systematic reviews as a way to clarify uncertainty
where there are several small con£icting studies. However, it is
not expected that systematic reviews alone could overcome the
limitations we have pointed to concerning the study duration
and the lack of comparative studies (Gri⁄ths et al, 2000). Quite
paradoxically, if systematic reviews concentrate on one of the
many treatments that have been tested for psoriasis, they may
risk giving undue emphasis to such treatments. Systematic re-
views alone are not expected to ¢ll the gap, and primary re-
search and high quality relevant RCTs are urgently needed.
CONCLUSION
In conclusion, we have identi¢ed an enormous range of treat-
ments that have been evaluated for psoriasis during the study per-
iod. Most studies were short-term and only a few compared
treatment options in di¡erent therapeutic classes. A heterogeneity
of outcome measures were also employed. Faced with this situa-
tion, it is hardly surprising that marked variations between cen-
ters and countries have been documented in the management of
psoriasis with many treatment decisions being based on such issues
as local traditions, individual preference and e¡ective marketing.
Our main focus was on reporting not on the ways the studies
were actually conducted. However, previous studies have docu-
mented that poor quality of reporting is strongly related to poor
trial quality (Juni et al, 2001). The four most important recommen-
dations when researchers and editors plan and publish future psor-
iasis trials are (i) to select for comparison an active intervention
restricting the use of placebo; (ii) to consider longer term studies,
e.g., at least six month duration; (iii) to adopt clinically relevant
outcomes such as duration of remission, major disease £are-ups, pa-
tient satisfaction; and (iv) to consider drop-outs in the analysis by
presenting both intention-to-treat and per-protocol analyzes.
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